Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 646 to 660 of 2011 results for nice guidelines

  1. Published guidance, NICE advice and quality standards

    Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards

  2. Step-by-step guide to registering as a stakeholder

    How to register as a stakeholder with NICE.

  3. Step-by-step guide to registering as a stakeholder

    How to register as a stakeholder with NICE.

  4. Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes (TA47)

    Evidence-based recommendations on glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) for treating acute coronary syndromes in adults.

    Technology appraisal guidance
    Last updated
    1 March 2010
    View recommendations

    Sections for TA47

  5. Stage 3: admission to the system

    In virtual wards, patients remain at home to receive hospital-level care. Our guidance can help you determine if patients are suitable for admission to the virtual wards system.

  6. Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)

    Evidence-based recommendations on evolocumab (Repatha) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.

    Technology appraisal guidance
    Published
    22 June 2016
    View recommendations

    Sections for TA394

  7. Management of vomiting in children and young people with gastroenteritis: ondansetron (ESUOM34)

    Summary of the evidence on ondansetron for the management of vomiting in children and young people with acute gastroenteritis

    Evidence summary
    Published
    7 October 2014

  8. How you can use our recommendations, tools and resources: cardiovascular disease

    How to use NICE guidance to reduce health inequalities in people experiencing cardiovascular disease (CVD).

  9. Padeliporfin for untreated localised prostate cancer (TA546)

    Evidence-based recommendations on padeliporfin (Tookad) for untreated, unilateral, low-risk prostate cancer in adults.

    Technology appraisal guidance
    Published
    21 November 2018
    View recommendations

    Sections for TA546

  10. Consultancy service

    Get expert advice and support from NICE International, part of the UK's National Institute for Health and Care Excellence, for a project in your country

  11. Experience: Dental services (IND289)

    This indicator covers patient experiences of dental services. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

    Network / system level indicators
    Published
    31 December 2023

  12. Key question: effective

    This resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.

  13. Clostridium difficile infection: risk with broad-spectrum antibiotics (ESMPB1)

    Summary of the evidence on the risk of using broad-specturm antibiotics associated with clostridium difficile infection

    Evidence summary
    Published
    17 March 2015

  14. Apixaban for preventing venous thromboembolism after hip or knee replacement surgery (TA245)

    Evidence-based recommendations on apixaban (Eliquis) for preventing venous thromboembolism after hip or knee replacement in adults.

    Technology appraisal guidance
    Published
    25 January 2012
    View recommendations

    Sections for TA245

  15. Antimicrobial prescribing: delafloxacin for acute bacterial skin and skin structure infections (ES32)

    Summary of the evidence on antimicrobial prescribing: delafloxacin

    Evidence summary
    Published
    5 January 2021